Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754448 | 1.00 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8523665 | 0.91 | MAPT (0.55) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20777511 | 0.86 | HTR5A (0.52) | CREBBPBRD4HTR5APARP1PARP10 | |
| SCHEMBL29622074 | 0.82 | CCNB2 (0.54) | CREBBPBRD4HTR5AMAPTCCNB2 | |
| SCHEMBL152281 | 0.82 | CCNB2 (0.54) | CREBBPBRD4HTR5AMAPTCCNB2 | |
| SCHEMBL3593984 | 0.78 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9911041 | 0.78 | HTR1A (0.49) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL98299 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL18885726 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3723532 | 0.77 | SRD5A1 (0.57) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023098880-A1 | FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2022109179-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-114436955-A | Tetrahydroquinoline and benzomorpholine derivatives or salts thereof, and preparation method and application thereof | 复旦大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021188907-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11046661-B2 | Method for producing lactam compound, and lactam compound produced thereby | INSTITUTE FOR BASIC SCIENCE (KR) | 2021-06-29 | — | — | US | disclosed |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| EP-1751116-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060199810-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005118558-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | NPC1 1062/4885MAPK13 3959/4885MAPK12 3198/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | NPC1 1132/4885MAPK13 2021/4885MAPK12 1909/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | NPC1 949/4885MAPK13 2369/4885MAPK12 1220/4885 |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | NPC1 3138/4885MAPK13 2633/4885MAPK12 2677/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | NPC1 1062/4885MAPK13 3959/4885MAPK12 3198/4885 |
| US-20060199810-A1 | Muscarinic agonists | CHRM3, CHRM5, CHRM2 | NPC1 1067/4885MAPK13 3852/4885MAPK12 3209/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | NPC1 1433/4885MAPK13 2544/4885MAPK12 1300/4885 |
| US-11046661-B2 | Method for producing lactam compound, and lactam compound produced thereby | SQLE, COASY, DHPS | NPC1 3709/4885MAPK13 4250/4885MAPK12 3592/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NPC1 3306/4885MAPK13 505/4885MAPK12 573/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | NPC1 3197/4885MAPK13 304/4885MAPK12 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.